A Study of the Efficacy and Safety of GB-0998 in Patients With Unexplained Recurrent Miscarriage
Status:
Completed
Trial end date:
2020-09-01
Target enrollment:
Participant gender:
Summary
The present survey was conducted to evaluate the efficacy and safety of
GB-0998(immunoglobulin) in the treatment of unexplained recurrent miscarriage in comparison
to placebo using a multicenter, double-blind, intergroup comparison method.